NovaBridge Biosciences Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 30

Employees

  • Stock Symbol
  • NBP

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $0.85
  • (As of Friday Closing)

NovaBridge Biosciences General Information

Description

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

Contact Information

Formerly Known As
Third Venture Biopharma, I-Mab Biopharma, I-Mab
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2440 Research Boulevard
  • Suite 400
  • Rockville, MD 20850
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 2440 Research Boulevard
  • Suite 400
  • Rockville, MD 20850
  • United States
+1 (240)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NovaBridge Biosciences Stock Performance

As of 13-Nov-2026, NovaBridge Biosciences’s stock price is $0.85. Its current market cap is $98.6M with 116M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.85 $0.83 $0.78 - $5.19 $98.6M 116M 483K -$0.69

NovaBridge Biosciences Financials Summary

As of 30-Jun-2026, NovaBridge Biosciences has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 17,740 233,859 (111,334) (238,368)
Revenue 0 0 0 632
EBITDA (122,808) (95,095) (56,204) (90,450)
Net Income (75,483) (46,269) (22,230) (207,729)
Total Assets 231,542 260,522 212,680 368,922
Total Debt 4,458 3,067 3,882 3,887
Public Fundamental Data provided by Morningstar, Inc. disclaimer

NovaBridge Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NovaBridge Biosciences‘s full profile, request access.

Request a free trial

NovaBridge Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to ide
Drug Discovery
Rockville, MD
30 As of 2025

Lexington, MA
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NovaBridge Biosciences Competitors (77)

One of NovaBridge Biosciences’s 77 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agenus Formerly VC-backed Lexington, MA
Valerio Therapeutics Formerly VC-backed Paris, France
Arcus Biosciences Formerly VC-backed Hayward, CA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
Redx Pharma Venture Capital-Backed Macclesfield, United Kingdom
You’re viewing 5 of 77 competitors. Get the full list »

NovaBridge Biosciences Patents

NovaBridge Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4143239-A1 Pharmaceutical compositions containing anti-cd47 antibodies Inactive 30-Apr-2020
EP-4143239-A4 Pharmaceutical compositions containing anti-cd47 antibodies Inactive 30-Apr-2020
EP-4048699-A1 Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof Inactive 22-Nov-2019
EP-4048699-A4 Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof Inactive 22-Nov-2019
WO-2021097800-A1 Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof Inactive 22-Nov-2019 C07K16/2827
To view NovaBridge Biosciences’s complete patent history, request access »

NovaBridge Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NovaBridge Biosciences Investments & Acquisitions (4)

NovaBridge Biosciences’s most recent deal was a Merger/Acquisition with BridgeBio for . The deal was made on 28-Oct-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
BridgeBio 28-Oct-2025 Merger/Acquisition Biotechnology
NovaBridge Biosciences (VIS-101, Novel Bifunctional Biologic in the United States) 20-Oct-2025 Corporate Asset Purchase Buildings and Property
TJ Biopharma 08-Feb-2024 Later Stage VC Drug Discovery
Tianzhenshi Biotechnology Company 23-Mar-2017 Buyout/LBO Biotechnology
To view NovaBridge Biosciences’s complete investments and acquisitions history, request access »

NovaBridge Biosciences ESG

Risk Overview

Risk Rating

Updated February, 28, 2023

32.29 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 16,421

Rank

Percentile

Pharmaceuticals

Industry

of 928

Rank

Percentile

Pharmaceuticals

Subindustry

of 456

Rank

Percentile

To view NovaBridge Biosciences’s complete esg history, request access »

NovaBridge Biosciences FAQs

  • When was NovaBridge Biosciences founded?

    NovaBridge Biosciences was founded in 2016.

  • Where is NovaBridge Biosciences headquartered?

    NovaBridge Biosciences is headquartered in Rockville, MD.

  • What is the size of NovaBridge Biosciences?

    NovaBridge Biosciences has 30 total employees.

  • What industry is NovaBridge Biosciences in?

    NovaBridge Biosciences’s primary industry is Drug Discovery.

  • Is NovaBridge Biosciences a private or public company?

    NovaBridge Biosciences is a Public company.

  • What is NovaBridge Biosciences’s stock symbol?

    The ticker symbol for NovaBridge Biosciences is NBP.

  • What is the current stock price of NovaBridge Biosciences?

    As of 13-Nov-2026 the stock price of NovaBridge Biosciences is $0.85.

  • What is the current market cap of NovaBridge Biosciences?

    The current market capitalization of NovaBridge Biosciences is $98.6M.

  • Who are NovaBridge Biosciences’s competitors?

    Agenus, Valerio Therapeutics, Arcus Biosciences, Immunocore Holdings, and Redx Pharma are some of the 77 competitors of NovaBridge Biosciences.

  • What is NovaBridge Biosciences’s annual earnings per share (EPS)?

    NovaBridge Biosciences’s EPS for 12 months was -$0.69.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process